CA Patent

CA3145888A1 — Ophthalmic formulations and uses thereof

Assigned to Individual · Expires 2020-02-06 · 6y expired

What this patent protects

Provided herein are ophthalmic formulations and eye drops that contain a telomerase activator as the active agent to increase telomerase activity. Also provided are methods for reducing the incidence of age-related eye conditions or for increasing viability of cells in the cornea…

USPTO Abstract

Provided herein are ophthalmic formulations and eye drops that contain a telomerase activator as the active agent to increase telomerase activity. Also provided are methods for reducing the incidence of age-related eye conditions or for increasing viability of cells in the corneal tissue by administering or contacting the ophthalmic formulation to one or both eyes in a subject.

Drugs covered by this patent

Patent Metadata

Patent number
CA3145888A1
Jurisdiction
CA
Classification
—
Expires
2020-02-06
Drug substance claim
No
Drug product claim
No
Assignee
Individual
Source
FDA Orange Book + USPTO grounding via Google Patents

Bibliographic data sourced from FDA Orange Book + USPTO public records. Plain-English summary generated by AI grounded in source text. Patent term extensions (PTR, SPC, pediatric) may shift the effective expiry. Not legal advice.

Track this patent

Get a daily-checked alert when vulnerability score, expiry, classification, or assignee changes. Email, Slack, or Teams delivery. Pro: 50 watches, Free: 3.